Charlotte Shaw
Medical · Bastrop, LANPI 1316219751
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 130 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $735 and has fallen 50.7% since, to $362 in 2025.
Across 130 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$370
- Novo Nordisk$241
- AstraZeneca$229
- Bayer$222
- Nestle Healthcare Nutrition Inc.$211
- Astellas Pharma US Inc$160
- plus $1K from 21 others
What the payments were for
- Food & beverage$2,512100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 24 | $370 |
| Novo Nordisk | 14 | $241 |
| AstraZeneca | 8 | $229 |
| Bayer | 11 | $222 |
| Nestle Healthcare Nutrition Inc. | 8 | $211 |
| Astellas Pharma US Inc | 9 | $160 |
| GSK | 8 | $151 |
| Merck | 5 | $102 |
| Avanir Pharmaceuticals, Inc. | 5 | $88 |
| Axsome Therapeutics, Inc. | 4 | $81 |
| Harmony Biosciences LLC | 3 | $75 |
| Lilly USA, LLC | 3 | $66 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $62 |
| Boehringer Ingelheim | 3 | $60 |
| Amgen | 3 | $59 |
| Pfizer | 3 | $57 |
| Exact Sciences | 3 | $50 |
| Novartis | 2 | $38 |
| Smith+Nephew | 2 | $33 |
| Otsuka America Pharmaceutical, Inc. | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Kowa Pharmaceuticals America, Inc. | 1 | $22 |
| Global Blood Therapeutics, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Insulet Corporation | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,512 in reported general payments places this provider in the 75th percentile of 253 medical providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 59 | $67,553 |
| MounjaroTirzepatide | 39 | $42,031 |
| KerendiaFinerenone | 39 | $33,428 |
| EliquisApixaban | 38 | $22,314 |
| LinzessLinaclotide | 24 | $21,598 |
| JardianceEmpagliflozin | 24 | $19,126 |
| TrintellixVortioxetine Hydrobromide | 20 | $13,743 |
| NuedextaDextromethorphan Hbr/Quinidine | 15 | $11,689 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $6,875 |
| TradjentaLinagliptin | 12 | $2,890 |
| Megestrol Acetate | 12 | $1,211 |
| Gabapentin | 100 | $1,183 |
| Memantine Hcl | 18 | $880 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 35 | $811 |
| Potassium Chloride | 40 | $621 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $241 | $67,55359 claims |
| Lilly USA, LLCMounjaro | $66 | $42,03139 claims |
| BayerKerendia | $222 | $33,42839 claims |
| PfizerEliquis | $57 | $22,31438 claims |
| Boehringer IngelheimJardiance, Tradjenta | $60 | $22,01636 claims |
| AbbVieLinzess | $370 | $21,59824 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $28 | $13,74320 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $88 | $11,68915 claims |
| AstraZenecaBreztri Aerosphere | $229 | $6,87511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 253 medical providers in Louisiana.
Other medical in Bastrop
- Kristi RobertBaton Rouge$486K
- Vickie RiceBaton Rouge$19K
- Mary McFerrenShreveport$16K
- Rachel RhinehartJefferson$16K
- Sydney FussellCovington$16K
- Thomas BriscoeLafayette$13K
- Seth HendrixShreveport$12K
- Jessica PelusoNatchitoches$12K
- Heather RoanBossier City$11K
- Emily FerraraBaton Rouge$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.